CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pilot Therapeutics Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pilot Therapeutics Holdings, Inc.
101 N. Chestnut Street, Suite 102
Phone: (336) 725-2222p:336 725-2222 WINSTON SALEM, NC  27101  United States Ticker: PLTTPLTT
This company ceased filing statements with the SEC on 3/22/2007.
Pilot’s board of directors elected to deregister its common stock and suspend its reporting obligations with the SEC under the Securities Exchange Act of 1934. The BOD believed the advantages of deregistering as a public company far outweighed any disadvantages. Factors that weighed in favor of Pilot deregistering included: the costs associated with the preparation and filing of periodic reports with the SEC; the anticipated increase in reporting and compliance costs associated with the Sarbanes-Oxley Act of 2002 and regulations promulgated thereunder; and the limited nature and extent of the trading in Pilot’s common stock.
Business Summary
Pilot Therapeutics Holdings, Inc. is a holding company for Pilot Therapeutics, Inc. and is a specialty pharmaceutical company. Through lipid profiling and metabolism, the Company has developed a proprietary, lipid and genomic profiling research platform, termed Functional Liponomics. Using Functional Liponomics, the Company is developing novel, branded, therapeutic, pharmaceutical and over-the-counter (OTC) medical food products that are specifically designed to address dysfunctional lipid metabolism in chronic human diseases such as asthma, coronary heart disease, allergic rhinitis, cancer, cystic acne and rheumatoid arthritis. Pilot expects to launch its first product, Airozin, for adults and children regionally in April 2003 and nationally by 2004.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200312/31/2002YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Terrance L.Little 7/23/2004 7/23/2004
President KeithWakeman 10/19/2007 10/19/2007
Chief Executive Officer RossConsaul 10/19/2007 10/19/2007
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Pilot Therapeutics Holdings, Inc.
PLTT

General Information
Number of Employees: 14 (As of 12/31/2002)
Outstanding Shares: 11,544,501 (As of 8/1/2003)
Shareholders: 326
Stock Exchange: OTC
Federal Tax Id: 562280858
Fax Number: (302) 655-5049
Email Address: info@pilott.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023